Company Overview
Phathom Pharmaceuticals, Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of treatments specifically targeting gastrointestinal diseases within the United States market. The company focuses its research and development efforts on VOQUEZNA, a therapeutic agent that has successfully completed Phase III clinical trials for the treatment of erosive gastroespectral reflux disease (GERD). Operating within the broader healthcare sector and the specialized biotechnology industry, Phathom leverages scientific innovation to address unmet medical needs in digestive health. With a market capitalization of $869.94M and an annual revenue of $175.11M, the company demonstrates significant scale for a mid-cap biopharma firm. The presence of 371 employees supports its operational infrastructure, indicating a substantial organizational footprint capable of managing complex drug development and commercialization activities.
Financial Health
The company reported a total revenue of $175.11M over the trailing twelve months, yet this revenue generated a net income of -$221,247,008 and an EBITDA of -$159,352,992. The substantial gap between positive revenue and negative net income reveals a high cost structure typical of biotechnology firms, where research, development, and clinical trial expenses heavily impact profitability before reaching the bottom line. Free cash flow stands at -$107,858,128, indicating that current operational expenditures and capital requirements exceed cash generation, which limits immediate financial flexibility but is often expected during the growth phase of drug development. The gross margin is 87.1%, suggesting high efficiency in the production or licensing of its core products, while the operating margin of -10.3% and profit margin of -126.3% reflect significant overhead costs and the dilutive nature of the company's current financial position. On the balance sheet, Phathom holds $129.97M in cash against $589.17M in debt, resulting in a debt-to-equity ratio that is not calculable (N/A) due to the equity structure, though the leverage is substantial relative to cash reserves. The current ratio of 1.73 indicates a conservative approach to short-term liquidity, as the company holds significantly more current assets than current liabilities, ensuring it can meet its immediate obligations without immediate distress. Return on Equity is N/A, while Return on Assets is -31.4%, revealing that the company's current asset base is generating negative returns, a metric that reflects the heavy investment required in the biotechnology sector rather than management inefficiency in the traditional sense.
Valuation Assessment
Phathom Pharmaceuticals carries a trailing P/E ratio of N/A due to its net loss, while the forward P/E is 6.83, implying that the market expects a significant turnaround in earnings trajectory to reach profitability in the near future. The price-to-book ratio is -1.80, which indicates that the stock is trading below its book value, a common characteristic for biotechnology companies with intangible assets and significant liabilities that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 4.97 and an EV/EBITDA of -8.43 suggest that the market is pricing the stock based on revenue potential and future optionality rather than current earnings power. The 52-week high is $18.31 and the 52-week low is $2.21, placing the stock in a wide trading range that reflects high volatility and potential for significant price swings based on clinical data or regulatory news. The beta of 0.56 indicates that the stock is less volatile than the broader market, suggesting it may offer a unique risk profile compared to larger, more established pharmaceutical peers.
Growth & Income
Revenue growth year-over-year stands at 94.1%, while earnings growth is N/A due to the company's current net loss, implying that the company is prioritizing top-line expansion and market share acquisition over immediate profit generation. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the firm reinvests all available earnings and cash reserves directly back into research and development to fuel future growth. This reinvestment strategy is typical for biotechnology companies in the growth phase, where capital is required to advance clinical trials and secure regulatory approvals for new indications. The overall growth and income profile is characterized by aggressive revenue expansion funded by existing cash reserves and debt, with no current reliance on dividend income for shareholders.